VERU (VERU)
$0.52
0.00081 (0.16%)
VERU Stock Quote Delayed 30 Minutes
VERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024
VERU stock results show that Veru beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$0.53
Market Cap
78.30M
PE Ratio
-1.97
EPS
-0.263
Volume (Avg. Vol.)
567,469
Day's Range
$0.51 - $0.53
52-Week Range
$0.45 - $1.92
Dividend & Yield
N/A (N/A)
VERU Stock Predictions, Articles, and VERU News
Why Is VERU Stock Up 3% Today?
Veru (VERU) stock is getting a boost on Friday after the company revealed plans to sell its ENTADFI capsule business for $20 million.
Why Is Veru (VERU) Stock Down 37% Today?
Veru (VERU) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off Friday morning with a breakdown of the biggest pre-market stock movers traders need to keep an eye on!
Why Is VERU Stock Up 8% Today?
With biopharma outfit Veru appointing a hero in the industry as Chairman of its advisory board, VERU stock may get interesting.
Why Is VERU Stock Down 50% Today?
The regulatory hammer is hitting VERU stock investors hard today as the FDA denies a crucial authorization for Veru's Covid-19 drug.
VERU Stock Soars 40% Despite Uncertainty Surrounding Covid-19 Drug
While the FDA may have some questions regarding Veru’s Covid-19 therapeutic, investors remain optimistic about VERU stock.
Why Is VERU Stock Up 36% Today?
Veru (VERU) stock is heading higher on Thursday as investors celebrate positive news in its earnings report for fiscal Q3 2022.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're taking a look at the biggest pre-market stock movers for Thursday that investors need to know about!
VERU Stock Pops on Clinical Trial Update
Veru (VERU) stock is on the move Wednesday after the company published results from its Phase 3 clinical trial of sabizabulin.
VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive
Veru (VERU) stock is on the move Wednesday following news of the biopharmaceutical company adding Joel Batten to its list of executives.
Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise
VERU stock's rapid upward trajectory could continue as Veru releases its fiscal results and marks a significant clinical milestone.
Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop
Short squeeze stocks are once again in focus this week as the bears continue to run wild in the stock market.
VERU Stock Pops on a Covid-19 Treatment Milestone
Veru (VERU) stock is rising higher on Wednesday following a recent ruling from the FDA concerning the company's Covid-19 treatment.
Veru Stock Could Face Difficulties If the Culper Research Report Is True
VERU stock could face major problems with investors if some of the glaring issues raised by the Culper Research report are true.
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.
Why Is Veru (VERU) Stock On the Move Again Today?
Veru (VERU) stock is continuing to move today with a few factors affecting the recent change in the biopharmaceutical company's shares.
